NeuropaceNPCE
NPCE
About: NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all its revenue from the sales of RNS System to hospitals facilities (typically Level 4 CECs) that implant RNS System.
Employees: 184
0
Funds holding %
of 7,139 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
2,500% more call options, than puts
Call options by funds: $260K | Put options by funds: $10K
350% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 4
126% more capital invested
Capital invested by funds: $103M [Q3] → $234M (+$130M) [Q4]
110% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 10
100% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]
29% more funds holding
Funds holding: 48 [Q3] → 62 (+14) [Q4]
19.2% more ownership
Funds ownership: 50.71% [Q3] → 69.91% (+19.2%) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$14
2%
upside
Avg. target
$16
16%
upside
High target
$17
23%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Wells Fargo Larry Biegelsen 66% 1-year accuracy 31 / 47 met price target | 23%upside $17 | Overweight Maintained | 30 Jan 2025 |
UBS Priya Sachdeva 67% 1-year accuracy 2 / 3 met price target | 23%upside $17 | Buy Initiated | 21 Jan 2025 |
JP Morgan Robbie Marcus 60% 1-year accuracy 12 / 20 met price target | 2%upside $14 | Overweight Maintained | 17 Dec 2024 |
Financial journalist opinion
Based on 8 articles about NPCE published over the past 30 days
Positive
Zacks Investment Research
1 day ago
NeuroPace (NPCE) Surges 5.8%: Is This an Indication of Further Gains?
NeuroPace (NPCE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Neutral
GlobeNewsWire
1 day ago
NeuroPace Completes Repurchase of 5.3 Million Shares of Its Common Stock from KCK Ltd.
MOUNTAIN VIEW, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it has completed the previously announced plan to repurchase 5,270,845 shares of the Company's common stock from KCK Ltd. The repurchase of these shares allowed for the organized sale by KCK Ltd. of all remaining shares it held in the Company. NeuroPace funded the repurchase of these shares using a portion of the proceeds from its recent underwritten public offering. NeuroPace also strengthened its balance sheet following the closing of the public offering, which the Company now anticipates will be sufficient to support its planned operations until achieving cash flow breakeven. Additionally, the Company terminated its current at-the-market (ATM) offering program.
Neutral
GlobeNewsWire
2 days ago
NeuroPace to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025
MOUNTAIN VIEW, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the fourth quarter and full year of 2024 after market close on Tuesday, March 4, 2025.
Neutral
GlobeNewsWire
3 days ago
NeuroPace Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
MOUNTAIN VIEW, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE) today announced the completion of its previously announced underwritten public offering of 7,475,000 shares of its common stock at a public offering price of $10.00 per share, including 975,000 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares.
Neutral
GlobeNewsWire
1 week ago
NeuroPace Announces Pricing of Public Offering of $65 Million of Common Stock
MOUNTAIN VIEW, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE) today announced the pricing of an underwritten public offering of 6,500,000 shares of its common stock at a public offering price of $10.00 per share.
Neutral
GlobeNewsWire
1 week ago
NeuroPace Announces Proposed Public Offering of $65 Million of Common Stock
MOUNTAIN VIEW, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE) today announced that it intends to offer and sell, in an underwritten public offering, $65 million of shares of its common stock. All of the shares are being offered by NeuroPace. In addition, NeuroPace intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Neutral
GlobeNewsWire
2 weeks ago
NeuroPace Announces Upcoming Oral Presentation of Data from the Post-Approval Study of the RNS System at the American Academy of Neurology 2025 Annual Meeting Being Held April 5th – 9th
MOUNTAIN VIEW, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that an abstract featuring data from the Post-approval Study of the RNS System has been selected for an oral presentation at the upcoming American Academy of Neurology (AAN) 2025 Annual Meeting, which is being held April 5th – 9th in San Diego.
Neutral
GlobeNewsWire
3 weeks ago
NeuroPace Issues 2025 Financial Guidance Targets
– 2025 revenue guidance of $92 million to $96 million – – 2025 gross margin guidance of 73% to 75% – – Three-year targets of 20% revenue CAGR and achievement of cash flow breakeven – MOUNTAIN VIEW, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today issued 2025 financial guidance targets at an in-person and virtual Investor Day today in New York, New York (a replay can be viewed virtually here, and the accompanying slide presentation can be accessed here).
Positive
Zacks Investment Research
1 month ago
NeuroPace (NPCE) Soars 9.1%: Is Further Upside Left in the Stock?
NeuroPace (NPCE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Neutral
GlobeNewsWire
1 month ago
NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2024 and Provides Business Updates
Preliminary unaudited revenue expected to be between $21.0 million and $21.5 million for Q4 2024, and between $79.4 million and $79.9 million for full year 2024
Charts implemented using Lightweight Charts™